Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 10/20 | 0.48 |
| ▸ | LGALS4 | P56470 | 4/20 | 0.48 |
| ▸ | FGF1 | P05230 | 1/20 | 0.47 |
| ▸ | LGALS9 | O00182 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 7/20 | 0.42 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316874 | 1.00 | LGALS3 (0.48) | LGALS3LGALS4FGF1LGALS9CA1 | |
| SCHEMBL3316862 | 1.00 | LGALS3 (0.48) | LGALS3LGALS4FGF1LGALS9CA1 | |
| SCHEMBL4787669 | 1.00 | LGALS3 (0.48) | LGALS3LGALS4FGF1LGALS9CA1 | |
| SCHEMBL9609370 | 0.86 | LGALS3 (0.44) | LGALS3LGALS4LGALS9CA1CA2 | |
| SCHEMBL28182370 | 0.84 | SLC5A2 (0.48) | LGALS9CA1CA2CA9SLC5A2 | |
| SCHEMBL7645735 | 0.83 | SLC5A2 (0.50) | LGALS9CA1CA2CA9SLC5A2 | |
| SCHEMBL8540246 | 0.83 | SLC5A2 (0.50) | LGALS9CA1CA2CA9SLC5A2 | |
| SCHEMBL5215790 | 0.83 | SLC5A2 (0.50) | LGALS9CA1CA2CA9SLC5A2 | |
| SCHEMBL14890371 | 0.83 | SLC5A2 (0.50) | LGALS9CA1CA2CA9SLC5A2 | |
| SCHEMBL29413019 | 0.83 | SLC5A2 (0.50) | LGALS9CA1CA2CA9SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | LGALS3 4191/4885LGALS4 4109/4885FGF1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.